Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis
The effect of intravenously administered immune globulin (IVIG) on patients with cystic fibrosis with an acute exacerbation of pulmonary infection was evaluated in a double-blind study. Patients at least 12 years of age, with chronic respiratory tract colonization with Pseudomonas aeruginosa and hos...
Gespeichert in:
| Veröffentlicht in: | The Journal of pediatrics 1989-02, Vol.114 (2), p.309-314 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 314 |
|---|---|
| container_issue | 2 |
| container_start_page | 309 |
| container_title | The Journal of pediatrics |
| container_volume | 114 |
| creator | Winnie, Glenna B. Cowan, Robert G. Wade, Nancy A. |
| description | The effect of intravenously administered immune globulin (IVIG) on patients with cystic fibrosis with an acute exacerbation of pulmonary infection was evaluated in a double-blind study. Patients at least 12 years of age, with chronic respiratory tract colonization with
Pseudomonas aeruginosa and hospitalized with a reduction in pulmonary function, were randomly assigned to receive 20% dextrose (control subjects: n=9) or 100 mg/kg IVIG (Gamimune) (experimental subjects: n=8) on days 1, 2, and 3; all patients received intravenous antibiotics and chest physiotherapy. There were no differences between groups on admission; patients had moderate to severe disease as measured by Shwachman-Kulczycki scores and pulmonary function tests. Both groups improved clinically. The IVIG treatment was associated with significant increases in forced vital capacity and forced expiratory volume in 1 second (
p |
| doi_str_mv | 10.1016/S0022-3476(89)80804-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78843792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347689808042</els_id><sourcerecordid>78843792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-cfe8149579489b23437ea5a7adaefd089796c186cbfebc5e224db5d2b215aabe3</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMoOl4eQehCRBfVXJo2WYmIl4EBF-o6JOmpRNp0TFLRtzfjDLN1dRbn-8_lQ-iU4CuCSX39gjGlJaua-kLIS4EFrkq6g2YEy6asBWO7aLZFDtBhjB8YY1lhvI_2qSScSjZDL3Ofgv4CP06xcMMweSje-9FMvfNFCqDTAD4VY1csp34YvQ4_BXxrC8Ho5EafQ76wPzE5W3TOhDG6eIz2Ot1HONnUI_T2cP9691Qunh_nd7eL0jIhU2k7EKSSvJGVkIayijWguW50q6FrsZCNrC0RtTUdGMuB0qo1vKWGEq61AXaEztdzl2H8nCAmNbhooe-1h_yOaoTIMyXNIF-DNt8XA3RqGdyQX1EEq5VM9SdTrUwpIdWfTLXKnW4WTGaAdpva2Mv9s01fR6v7LmhvXdxiDeWcCZGxmzUGWcaXg6CideAttC6ATaod3T-H_ALMf5MH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78843792</pqid></control><display><type>article</type><title>Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Winnie, Glenna B. ; Cowan, Robert G. ; Wade, Nancy A.</creator><creatorcontrib>Winnie, Glenna B. ; Cowan, Robert G. ; Wade, Nancy A.</creatorcontrib><description>The effect of intravenously administered immune globulin (IVIG) on patients with cystic fibrosis with an acute exacerbation of pulmonary infection was evaluated in a double-blind study. Patients at least 12 years of age, with chronic respiratory tract colonization with
Pseudomonas aeruginosa and hospitalized with a reduction in pulmonary function, were randomly assigned to receive 20% dextrose (control subjects: n=9) or 100 mg/kg IVIG (Gamimune) (experimental subjects: n=8) on days 1, 2, and 3; all patients received intravenous antibiotics and chest physiotherapy. There were no differences between groups on admission; patients had moderate to severe disease as measured by Shwachman-Kulczycki scores and pulmonary function tests. Both groups improved clinically. The IVIG treatment was associated with significant increases in forced vital capacity and forced expiratory volume in 1 second (
p<0.01) and with greater percent improvement in forced expiratory volume and forced expiratory flow (25% to 75%) (
p<0.05). There was no effect on length of hospitalization (18.3±11.9 days control vs 17.6±6.5 experimental). The C3 level was decreased at discharge In IVIG-treated patients; circulating immune complex levels were unchanged. One patient in each group experienced side effects. There were no differences on follow-up at 6 weeks. We conclude that IVIG infusion early in treatment for pulmonary exacerbations in cystic fibrosis patients with moderate to severe disease may be associated with greater improvement in pulmonary function than standard treatment alone.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(89)80804-2</identifier><identifier>PMID: 2915293</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Biological and medical sciences ; Cystic Fibrosis - complications ; Cystic Fibrosis - immunology ; Cystic Fibrosis - physiopathology ; Double-Blind Method ; Forced Expiratory Volume ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunization, Passive ; Immunoglobulin G - analysis ; Immunoglobulins - administration & dosage ; Injections, Intravenous ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Other diseases. Semiology ; Pseudomonas Infections - immunology ; Pseudomonas Infections - physiopathology ; Pseudomonas Infections - therapy ; Random Allocation ; Vital Capacity</subject><ispartof>The Journal of pediatrics, 1989-02, Vol.114 (2), p.309-314</ispartof><rights>1989 The C. V. Mosby Company</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-cfe8149579489b23437ea5a7adaefd089796c186cbfebc5e224db5d2b215aabe3</citedby><cites>FETCH-LOGICAL-c389t-cfe8149579489b23437ea5a7adaefd089796c186cbfebc5e224db5d2b215aabe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0022-3476(89)80804-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7255388$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2915293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Winnie, Glenna B.</creatorcontrib><creatorcontrib>Cowan, Robert G.</creatorcontrib><creatorcontrib>Wade, Nancy A.</creatorcontrib><title>Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>The effect of intravenously administered immune globulin (IVIG) on patients with cystic fibrosis with an acute exacerbation of pulmonary infection was evaluated in a double-blind study. Patients at least 12 years of age, with chronic respiratory tract colonization with
Pseudomonas aeruginosa and hospitalized with a reduction in pulmonary function, were randomly assigned to receive 20% dextrose (control subjects: n=9) or 100 mg/kg IVIG (Gamimune) (experimental subjects: n=8) on days 1, 2, and 3; all patients received intravenous antibiotics and chest physiotherapy. There were no differences between groups on admission; patients had moderate to severe disease as measured by Shwachman-Kulczycki scores and pulmonary function tests. Both groups improved clinically. The IVIG treatment was associated with significant increases in forced vital capacity and forced expiratory volume in 1 second (
p<0.01) and with greater percent improvement in forced expiratory volume and forced expiratory flow (25% to 75%) (
p<0.05). There was no effect on length of hospitalization (18.3±11.9 days control vs 17.6±6.5 experimental). The C3 level was decreased at discharge In IVIG-treated patients; circulating immune complex levels were unchanged. One patient in each group experienced side effects. There were no differences on follow-up at 6 weeks. We conclude that IVIG infusion early in treatment for pulmonary exacerbations in cystic fibrosis patients with moderate to severe disease may be associated with greater improvement in pulmonary function than standard treatment alone.</description><subject>Biological and medical sciences</subject><subject>Cystic Fibrosis - complications</subject><subject>Cystic Fibrosis - immunology</subject><subject>Cystic Fibrosis - physiopathology</subject><subject>Double-Blind Method</subject><subject>Forced Expiratory Volume</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Immunoglobulin G - analysis</subject><subject>Immunoglobulins - administration & dosage</subject><subject>Injections, Intravenous</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Other diseases. Semiology</subject><subject>Pseudomonas Infections - immunology</subject><subject>Pseudomonas Infections - physiopathology</subject><subject>Pseudomonas Infections - therapy</subject><subject>Random Allocation</subject><subject>Vital Capacity</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKxDAUhoMoOl4eQehCRBfVXJo2WYmIl4EBF-o6JOmpRNp0TFLRtzfjDLN1dRbn-8_lQ-iU4CuCSX39gjGlJaua-kLIS4EFrkq6g2YEy6asBWO7aLZFDtBhjB8YY1lhvI_2qSScSjZDL3Ofgv4CP06xcMMweSje-9FMvfNFCqDTAD4VY1csp34YvQ4_BXxrC8Ho5EafQ76wPzE5W3TOhDG6eIz2Ot1HONnUI_T2cP9691Qunh_nd7eL0jIhU2k7EKSSvJGVkIayijWguW50q6FrsZCNrC0RtTUdGMuB0qo1vKWGEq61AXaEztdzl2H8nCAmNbhooe-1h_yOaoTIMyXNIF-DNt8XA3RqGdyQX1EEq5VM9SdTrUwpIdWfTLXKnW4WTGaAdpva2Mv9s01fR6v7LmhvXdxiDeWcCZGxmzUGWcaXg6CideAttC6ATaod3T-H_ALMf5MH</recordid><startdate>19890201</startdate><enddate>19890201</enddate><creator>Winnie, Glenna B.</creator><creator>Cowan, Robert G.</creator><creator>Wade, Nancy A.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19890201</creationdate><title>Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis</title><author>Winnie, Glenna B. ; Cowan, Robert G. ; Wade, Nancy A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-cfe8149579489b23437ea5a7adaefd089796c186cbfebc5e224db5d2b215aabe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Biological and medical sciences</topic><topic>Cystic Fibrosis - complications</topic><topic>Cystic Fibrosis - immunology</topic><topic>Cystic Fibrosis - physiopathology</topic><topic>Double-Blind Method</topic><topic>Forced Expiratory Volume</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Immunoglobulin G - analysis</topic><topic>Immunoglobulins - administration & dosage</topic><topic>Injections, Intravenous</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Other diseases. Semiology</topic><topic>Pseudomonas Infections - immunology</topic><topic>Pseudomonas Infections - physiopathology</topic><topic>Pseudomonas Infections - therapy</topic><topic>Random Allocation</topic><topic>Vital Capacity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Winnie, Glenna B.</creatorcontrib><creatorcontrib>Cowan, Robert G.</creatorcontrib><creatorcontrib>Wade, Nancy A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Winnie, Glenna B.</au><au>Cowan, Robert G.</au><au>Wade, Nancy A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1989-02-01</date><risdate>1989</risdate><volume>114</volume><issue>2</issue><spage>309</spage><epage>314</epage><pages>309-314</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>The effect of intravenously administered immune globulin (IVIG) on patients with cystic fibrosis with an acute exacerbation of pulmonary infection was evaluated in a double-blind study. Patients at least 12 years of age, with chronic respiratory tract colonization with
Pseudomonas aeruginosa and hospitalized with a reduction in pulmonary function, were randomly assigned to receive 20% dextrose (control subjects: n=9) or 100 mg/kg IVIG (Gamimune) (experimental subjects: n=8) on days 1, 2, and 3; all patients received intravenous antibiotics and chest physiotherapy. There were no differences between groups on admission; patients had moderate to severe disease as measured by Shwachman-Kulczycki scores and pulmonary function tests. Both groups improved clinically. The IVIG treatment was associated with significant increases in forced vital capacity and forced expiratory volume in 1 second (
p<0.01) and with greater percent improvement in forced expiratory volume and forced expiratory flow (25% to 75%) (
p<0.05). There was no effect on length of hospitalization (18.3±11.9 days control vs 17.6±6.5 experimental). The C3 level was decreased at discharge In IVIG-treated patients; circulating immune complex levels were unchanged. One patient in each group experienced side effects. There were no differences on follow-up at 6 weeks. We conclude that IVIG infusion early in treatment for pulmonary exacerbations in cystic fibrosis patients with moderate to severe disease may be associated with greater improvement in pulmonary function than standard treatment alone.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>2915293</pmid><doi>10.1016/S0022-3476(89)80804-2</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 1989-02, Vol.114 (2), p.309-314 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78843792 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Biological and medical sciences Cystic Fibrosis - complications Cystic Fibrosis - immunology Cystic Fibrosis - physiopathology Double-Blind Method Forced Expiratory Volume Gastroenterology. Liver. Pancreas. Abdomen Humans Immunization, Passive Immunoglobulin G - analysis Immunoglobulins - administration & dosage Injections, Intravenous Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Other diseases. Semiology Pseudomonas Infections - immunology Pseudomonas Infections - physiopathology Pseudomonas Infections - therapy Random Allocation Vital Capacity |
| title | Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T23%3A25%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20immune%20globulin%20treatment%20of%20pulmonary%20exacerbations%20in%20cystic%20fibrosis&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Winnie,%20Glenna%20B.&rft.date=1989-02-01&rft.volume=114&rft.issue=2&rft.spage=309&rft.epage=314&rft.pages=309-314&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/S0022-3476(89)80804-2&rft_dat=%3Cproquest_cross%3E78843792%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78843792&rft_id=info:pmid/2915293&rft_els_id=S0022347689808042&rfr_iscdi=true |